Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Biophytis SA (EM) BPTSY

Healthcare Biotechnology
Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients with age-related diseases. The company’s lead drug candidate is the BIO101 to treat obesity, respiratory infections due to Covid-19, sarcopenia, and Duchenne Muscular Dystrophy (DMD). It has a collaboration agreement... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (EXPM:BPTSY)

Biophytis Targets Mobility Restoration in Patients with Obesity

Newsfile April 22, 2025

Biophytis Confirms the Launch of the Phase 2 OBA Clinical Trial in Obesity

Newsfile April 9, 2025

Biophytis Announces New Non-Clinical Data Further Supporting Its Mission to Pioneer the Restoration of Mobility in Patients with Obesity

Newsfile March 24, 2025

Biophytis Revolutionizes Sarcopenia

Newsfile March 17, 2025

Biophytis Announces its Participation in the 15th International Conference on Frailty and Sarcopenia Research (ICFSR)

Newsfile February 25, 2025

Biophytis Unveils Its Outlook Strategies for 2025

Newsfile February 11, 2025

Biophytis Announces Its Participation to the BIOMED FORUM Investor Conference

Newsfile January 27, 2025

Biophytis and AskHelpU Sign a Co-Development Agreement in Rare Neuromuscular Diseases in China

Newsfile January 21, 2025

Biophytis Enters Exclusive Negotiations with a Chinese Pharmaceutical Company to License BIO101

Newsfile January 14, 2025
View More News ››

Opinion & Analysis (EXPM:BPTSY)

No current opinion is available.
View More Opinion ››

Bullboard Posts (EXPM:BPTSY)

Up over 30% Friday Repairs lungs after COVID-19

Lots of chatter on this one , pretty speculative but probably going to attract lots of swing traders and such? Bought a position two...
askretka - December 17, 2023
View more Bullboard ››

Silver North Resources Ltd.

Silver North Resources Ltd.

Silver North Resources Ltd., an exploration stage company, acquires and explores mineral properties. It explores for gold ...
View More »